Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 7, 2006

Integrated BioPharma and Fraunhofer CMB Move Forward on Flu Vaccine Project

  • Integrated BioPharma (INB) and the Fraunhofer USA Center for Molecular Biotechnology (FCMB) report the successful validation of their plant-based technology platform for the production of human therapeutic proteins and their further agreement to now use it to engineer and produce vaccines against influenza.

    The AIPwLV™ platform was developed for INB by FCMB over the last three years.  It uses nongenetically modified plants as a medium for the production of vaccine antigens.

    “Unlike vaccine technologies currently in use,” points out Vidadi Yusibov, executive director of FCMB, “the AIPwLV platform enables practically limitless scalability of production of target antigens for vaccines against diseases, such as influenza, relatively quickly after identification of the active strain thereby significantly increasing the availability of efficacious vaccines for large-scale inoculations.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »